GPC3 and hepatocellular carcinoma: In this context, the performance of immunohistochemical marker developed to discriminate high-grade dysplastic nodules from very early HCC (like glutamine synthase, glypican 3 or hsp70) on cirrhosis remains poorly explored to differentiate HCA from very well differenciated HCC on normal liver and should be used with caution [38].